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Background:  Statins reduce systemic CV events and are associated with lower rates of limb ischemic events in observational studies. We 
hypothesized that high intensity statin (HS) would be associated with greater ischemic protection relative to low intensity statin (LS) or no 
statin (NS) in patients with PAD.
methods:  TRA2°P-TIMI 50 was a multinational, randomized, double-blind, placebo controlled trial of vorapaxar in stable patients including 
5,845 with a history of PAD. We evaluated statin therapy at baseline and systemic and limb ischemic events at 3 years using propensity 
score adjustment.
results:  There were 875 (15%) on no statin (NS) and 4,970 (85%) on a statin. Of those, dose was ascertainable in 3,654 (74%) with 
2,475 (68%) on LS and 1,179 (32%) on HS. The risk of CVD/MI/Stroke and mortality was lower with statin therapy with significantly lower 
rates with HS vs NS (Figure 1a) and trends with LS vs NS (Figure 1b). ALI and amputation showed numeric trends with statin intensity but 
differences were not statistically significant. Statin therapy was associated with significantly lower rates of peripheral revasc with the lowest 
rates with HS versus NS (Figure 1a and 1b).
conclusion:  In patients with PAD, statin therapy is associated with lower rates of systemic ischemic events and limb revascularizations 
with the clearest benefit with HS. These data support guideline recommendations to treat all patients with PAD with high-intensity statin 
therapy.
